department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Adempas · pharmadog

pharmadog
drugs
Adempas

drug

patient view →

riociguat

Marketedupdated 2mo ago

by Bayer HealthCare Pharmaceuticals Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Adempas

generic

riociguat

indication

Chronic Thromboembolic Pulmonary Hypertension

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 58m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 4, 2026

150 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (20)

Feb 18, 2034compositionUS 10662188
Feb 18, 2034compositionUS 10662188
Feb 18, 2034compositionUS 10662188
Feb 18, 2034compositionUS 10662188
Feb 18, 2034compositionUS 10662188
Feb 18, 2034compositionUS 11203593
Feb 18, 2034compositionUS 11203593
Feb 18, 2034compositionUS 11203593
Feb 18, 2034compositionUS 11203593
Feb 18, 2034compositionUS 11203593
Feb 18, 2034formulationUS 12503469
Feb 18, 2034formulationUS 12503469
Feb 18, 2034formulationUS 12503469
Feb 18, 2034formulationUS 12503469
Feb 18, 2034formulationUS 12503469
Dec 4, 2026compositionUS 7173037150d
Dec 4, 2026compositionUS 7173037150d
Dec 4, 2026compositionUS 7173037150d
Dec 4, 2026compositionUS 7173037150d
Dec 4, 2026compositionUS 7173037150d

Trials studying riociguat

phase4Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPHterminatedn=30
phase3Riociguat in Children With Pulmonary Arterial Hypertension (PAH)active not recruitingn=24
phase2Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplastycompletedn=10
phase2Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAHterminatedn=35
phase3Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPHrecruitingn=15
phase4A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.completedn=18
phase2A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunctioncompletedn=202
phase2Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)completedn=22

more trials →